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Abstract 
Objective: To investigate the impact of prenatal antidepressant exposure on behavioural 
problems in children at 7-years of age. 
Design: Nationwide population-based study 
Setting: Danish National Birth Cohort 
Population: A cohort of 49,178 pregnant women recruited between 1996 and 2002.  
Methods: Data obtained from computer-assisted telephone interviews twice during 
pregnancy were used to identify children born to 1) depressed women who took 
antidepressants during pregnancy (N=210), 2) depressed women who did not take any 
antidepressants during pregnancy (N=231), and 3) nondepressed, healthy women 
(N=48,737). Childhood behavioural problems at 7-years of age were examined using the 
validated Danish parent-report version of the Strengths and Difficulties Questionnaire (SDQ).  
Main outcome measures: SDQ 
Results: No associations were observed between prenatal antidepressant exposure and 
abnormal SDQ scores for overall problem behaviour (aRR 1.00; 0.49, 2.05), 
hyperactivity/inattention (aRR 0.99; 0.56, 1.75), or peer problems (aRR 1.04; 0.57, 1.91). 
While prenatal antidepressant exposure appeared to be associated with abnormal SDQ scores 
on the subscales of emotional symptoms (aRR 1.68; 1.18, 2.38) and conduct problems (aRR 
1.58; 1.03, 2.42), these associations were significantly attenuated following adjustment for 
antenatal mood status (aRR 1.20; 0.85, 1.70 and aRR 1.19; 0.77, 1.83 respectively). 
Untreated prenatal depression was associated with an increased risk of all behavioural 
outcomes evaluated compared to unexposed children, with significant attenuation following 
adjustment for antenatal mood status.  
Conclusion: The results of this study suggest that independent of maternal illness, prenatal 
antidepressant exposure is not associated with an increased risk of behavioural problems in 
children at 7-years of age. 
 
Key Words: Antidepressive agents; prenatal exposure; pregnancy; child development; 
selective serotonin reuptake inhibitors  
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Over the past 10-15 years there has been a substantial increase in the use of 
antidepressants during pregnancy worldwide. In Denmark, antidepressant use during 
pregnancy has increased from 0.2% to 3.2% from 1997 to 2010,1 a trend mirrored in other 
countries such as the United States, where use during pregnancy has increased from 2% to 
7.6% from 1996 to  2005.2 Numerous studies have investigated various maternal and neonatal 
outcomes associated with prenatal antidepressant exposure, but developmental outcomes of 
the children are less well studied. The potential long-term effects of prenatal antidepressant 
exposure is of concern given its effect on serotonin (5-HT), which may affect neurogenesis, 
migration and differentiation of neurons in the fetal brain.3-5  
Evidence to date is equivocal in relation to the impact of prenatal antidepressant 
exposure on child neurodevelopment, given major differences in study design, patterns of 
antidepressant use, outcome measures and adjustment for confounding.3 In particular, few 
studies have evaluated developmental outcomes in offspring beyond 5-years of age. Data 
from the Danish National Birth Cohort (DNBC) has previously been utilised to evaluate 
developmental outcomes among children aged 6 and 19 months of age following prenatal 
antidepressant exposure, with developmental outcomes assessed within normal ranges.6 A 
further follow-up study of a sub-cohort of these children aged 4- to 5- years of age also 
identified no differences in behavioural or emotional problems in early childhood.7 Given 
these developmental measures in early age (whether normal or abnormal) may not accurately 
predict later developmental problems, there is a need for continuous long-term assessment of 
outcomes. In light of this, we expanded the follow-up time to evaluate the association 
between maternal antidepressant use during pregnancy and behavioural problems in children 
at 7-years of age. 
 
Methods 
This study included mother-child dyads participating in the DNBC, an ongoing 
nationwide, follow-up study of pregnant women and their children.8 More than 100,000 
pregnancies were included from 1996 to 2002, with 60% of invited pregnant women agreeing 
to participate. 
Women reported on medication use during early pregnancy in a self-administered 
questionnaire (at approx. 6-10 weeks of gestation). Following consent, women were 
interviewed by telephone twice during pregnancy, at 17 and 32 weeks gestation, and twice 
after pregnancy, when their children were 6 and 18 months old. The cohort has been 
described elsewhere.8 A self-administered questionnaire completed by parents (mainly 
mothers) was used to follow-up children at age 7. All questionnaires are available from 
www.dnbc.dk. 
Women eligible for this study were those who signed the consent form and 
participated in both prenatal interviews (N=82 687). We excluded women who did not give 
birth to live-born singletons (N=1 872) or who were taking psychotropic medications other 
than antidepressants (N=756), leaving a final study population of 80 107 women. Follow-up 
data on children at 7-years of age were available for 49 178 (61%) of the eligible cohort. 
 
Exposure variables 
Use of antidepressants was defined as self-reported use of any drugs in World Health 
Organization-defined Anatomic Therapeutic Chemical Classification System group N06A 
during pregnancy.9 Information on drug use was coded either using predefined names or in a 
text string recorded by the interviewer and later coded for analysis by the investigators. 
Women were classified as exposed if they reported taking an antidepressant at any stage 
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during pregnancy.  
Presence of depression during pregnancy was identified based on maternal self-report, 
according to questions asked at the 2 prenatal interviews. In the first interview women were 
asked: 1) Have you ever suffered from a mental disorder or neurosis?; 2) Did you see a 
medical doctor or psychologist for the disorder?; 3) What was the name of the disorder?; and 
4) Have you experienced symptoms of the disorder during pregnancy?. In the second 
interview women were asked whether they had experienced a mental disorder during 
pregnancy; if they had, they were asked to disclose the diagnosis.  
Based on these data, we assigned the offspring to one of three groups: 1) children 
whose mothers reported antidepressant use during pregnancy (‘antidepressant exposure’) 2) 
children whose mothers reported having prenatal depression but no antidepressant use during 
pregnancy (‘untreated depression’), and 3) children whose mothers reported no prenatal 
depressant and no antidepressant use during pregnancy (‘unexposed’). 
 
Outcome variable 
Behavioural problems were estimated using the validated Danish parent-report 
version of the Strengths and Difficulties Questionnaire (SDQ).10,11 Compared to diagnostic 
interviews,  the parent-report version of the SDQ has been demonstrated to have excellent 
discrimination for the identification of emotional (AUC 0.80; 95%CI 0.72-0.89) and 
behavioural (AUC 0.89; 95%CI 0.81-0.97) disorders.11 We analysed the SDQ score in the 
following five subscales ranging from 0 to 10: emotional, conduct, peer relationship and 
hyperactivity/inattention problems, and pro-social skills. The sum of problem scores 
corresponding to the first four subscales constituted the total difficulties SDQ score, ranging 
from 0 to 40. Descriptions of the subgroups can be found at www.sdqinfo.org. The total SDQ 
score and each subscale score were coded as normal, borderline or abnormal according to 
cut-offs outlined in the manual for SDQ. We combined normal and borderline scores in the 
dichotomised measure, considering abnormal score as the diverging score, representing 
values greater than the 90th percentile. 11 
 
Covariates 
Information on maternal age, parity, smoking status and pre-pregnancy weight and height 
was obtained from the first prenatal interview. Parity was categorised as either nulliparous (0) 
or multiparous (≥1). Smoking was categorised according to number of cigarettes smoked on 
average each day (none, 1-10 cigarettes and >10 cigarettes per day). Maternal pre-pregnancy 
BMI was coded into three categories (<25; 25 to 29, and ≥30). The socioeconomic status 
score was defined as described by Bech et al 12 by using data from the first prenatal interview. 
The highest socioeconomic status score of either the woman or her partner was included in 
the models, coded as high, middle, and low. Antenatal mood was evaluated using a modified 
version of the short version of the Symptom Checklist (SCL-8d).13 Mood was assessed by 
nine questions, each covering the time period since the beginning of pregnancy. Answers (no 




We used causal diagrams (directed acyclic graphs) to guide selection of potential 
covariates for which to control.15, 16 The first adjusted model included information on the 
following covariates: child sex, maternal age, parity, smoking status, socioeconomic status, 
and alcohol consumption during pregnancy. The second adjusted model also included 
antenatal mood. The sample size did not allow for stratification according to individual 
antidepressant type. 
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We compared SDQ estimates of behavioural problems in the three exposure groups 
using a generalised linear model (Poisson distribution) with robust variance estimates, with 
resulting relative risks (RR) and 95% confidence intervals (CIs). The sensitivity of the results 
to patterns of attrition (missing follow-up data) was examined using inverse probability 
weighting.17 To assess whether loss to follow-up biased our results, we used logistic 
regression (complete data vs. lost to follow-up as outcome) to determine weights for each 
individual using the inverse probability of response.17 Complete follow-up data was predicted 
based on exposure to antidepressants or untreated depression during pregnancy, maternal age, 
parity, smoking status, socioeconomic status, antenatal mood, and child sex. The individual 
weighting factor for these covariates (their inverse probability) was used as a sample 
weighting adjustment in later sensitivity analyses. Statistical analyses were performed using 
Stata 11.1 (Stata, College Station, TX, USA). 
 
Results:  
Of the 80,107 pregnant women eligible for the study, 395 were exposed to 
antidepressants, 474 had untreated depression, and 79,238 were unexposed. Rates of loss to 
follow-up at 7-years of age were greatest among those with antidepressant exposure (47%) 
and with untreated depression (51%), compared to those who were unexposed (38%) (Table 
S1).  
We studied the children of 210 mothers who were exposed to antidepressants and 
compared these to 231 children of mothers with untreated depression, and 48,737 children of 
mothers with no prenatal depression and no use of antidepressants during pregnancy 
(unexposed). Among the 210 women treated with antidepressants, 173 used one type of SSRI 
only (fluoxetine, n=45; citalopram, n=43; paroxetine, n=43; sertraline, n=42), 12 used only 
TCAs, and 19 used another type of antidepressant only (e.g. venlafaxine). Six used 
combinations of SSRIs, TCAs, and other antidepressants.  
Women taking antidepressants during pregnancy were more likely to be older and of 
higher socioeconomic status than women with untreated depression, and were more likely to 
be smokers, not to drink alcohol, and be of lower socioeconomic status compared to 
unexposed women (Table 1). Importantly, women with untreated depression reported 
significantly more antenatal mood symptoms during pregnancy than women taking 
antidepressants, with unexposed women reporting the fewest symptoms (Table S1 and Table 
S2).  
The age of children at follow-up (mean ± SD, years) was similar across the 
antidepressant (7.1 ± 0.1), untreated maternal depression (7.2 ± 0.1) and unexposed (7.2 ± 
0.1) groups (P = 0.142). Abnormal SDQ scores for each of the behavioural outcomes 
assessed were most common among children exposed to untreated antenatal depression 
(Figure 1). When compared to children of unexposed mothers, prenatal antidepressant 
exposure appeared to be associated with abnormal SDQ scores on the subscales of emotional 
symptoms (aRR 1.68; 1.18, 2.38) and conduct problems (aRR 1.58; 1.03, 2.42), however, 
these associations were significantly attenuated following adjustment for antenatal mood 
status (aRR 1.20; 0.85, 1.70 and aRR 1.19; 0.77, 1.83 respectively) (Table 2 and 3). No 
associations were observed between prenatal antidepressant exposure and abnormal SDQ 
scores for overall problem behaviour (aRR 1.00; 0.49, 2.05), hyperactivity/inattention (aRR 
0.99; 0.56, 1.75), or peer problems (aRR 1.04; 0.57, 1.91), when compared to children of 
unexposed mothers. Untreated prenatal depression was associated with an increased risk of 
all behavioural outcomes evaluated compared to unexposed children, with significant 
attenuation following adjustment for antenatal mood status (Table 2 and 3). Sensitivity 
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analyses undertaken using inverse probability weighting to account for loss to follow-up 
identified no major differences between the weighted and non-weighted results (Table S3). 
No significant differences in the risk of behavioural problems were evident following 
stratifying of antidepressant use according to first trimester exposure only or second/third 
trimester exposure (Table S4). 
Discussion: 
Main findings 
After adjustment for maternal factors, including antenatal mood, prenatal 
antidepressant exposure was not significantly associated with an increased risk of behavioural 
difficulties in children at 7-years of age. In light of these findings, our study adds to a 
growing body of evidence that prenatal antidepressant exposure does not appear to be 
significantly associated with negative effects on neurodevelopment in children up until 7-
years of age.6, 7, 18-25 Outcomes assessed to date range from developmental milestones, 
cognitive function, behaviour and psychomotor development. While the evidence is 
encouraging, it is still only based on a relatively small number of exposed children (<2000) 
involved in prospective cohort studies. Data pertaining to other neurodevelopmental 
outcomes are still lacking.  
Strengths and Limitations 
Our study had the strength of prospectively obtained information and that women 
were unaware of the hypothesis of the study when reporting behaviour when the children 
were 7-years of age. Furthermore, the inclusion of women with untreated depression enabled 
the estimation, to some extent, of the effects of prenatal antidepressant exposure independent 
from underlying maternal illness.  
The reliance of parent-reported SDQ as a proxy for emotional or behavioural 
problems in the offspring represents a study limitation, however, the intention was not to 
utilise SDQ scores to predict whether the children had an underlying psychiatric disorder, but 
to identify behavioural problems in groups of children characterised by their prenatal 
exposure. The main utility of SDQ scores lies in the ability to undertake comparisons 
between scores in different groups, not in the unique SDQ score for each individual.  It is 
likely that standardised neuropsychological testing may have detected more subtle changes in 
child behavioural problems than the SDQ score. However, while independent observation 
could overcome potential bias according to parental self-report, it may lead to the 
introduction of selection bias as not all parent’s may agree to spending the necessary time on 
testing.   
A further limitation of using parental report is that parental state of mind at the time of 
completing 7- year follow-up questionnaire may have influenced the parent’s view of the 
child and an abnormal SDQ score may reflect perceptions rather than the child’s actual 
problems. It was not possible to investigate this as a potential source of reporting bias as no 
data were available on parental mood at the time of completing the 7-year follow-up 
questionnaire. However, in our previous study involving a smaller cohort of children with 
prenatal antidepressant exposure, we did not observe any differences in maternal reports of 
child behaviours at 4- to 5-years of age according to whether they were evaluated as having 
normal or abnormal depressive symptoms at the time of questionnaire completion.7 
While this study represents the largest cohort of children to be investigated following 
prenatal antidepressant exposure, a relative limitation of this study remains the inability to 
generate precise risk estimates and to adjust for a number of potential confounders and/or 
covariates due to the small number of children in the antidepressant and untreated depression 
exposed groups. This makes it difficult to demonstrate statistically significant differences 
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among the two smaller prenatal antidepressant exposure and untreated maternal depression 
groups, despite clinically significant differences being apparent. The relatively low 
prevalence of antidepressant use is reflective of the low SSRI use in Denmark during the 
study period, which has been reported in other studies.6, 26 Furthermore, it is possible that 
women with an underlying psychiatric illness, such as depression, were less likely to consent 
to participate in the study, leading to the observed low prevalence of antidepressant use and 
untreated depression.  
Depression and the use of antidepressants may be associated with a variety of factors 
that may influence child development. While the inclusion of a control group of women with 
untreated depression, together with the adjustment for antenatal mood, accounted for 
confounding by the indication for treatment to some extent, residual confounding may still 
remain. It is possible that appropriate management of depression during and after pregnancy 
through the use of either non-pharmacological and/or pharmacological treatments may be 
associated with differing rates of abnormal behavioural outcomes in the children. As the 
focus of this study was on determining the relative impact of prenatal antidepressant exposure 
on child behavioural outcomes, we did not evaluate the impact of maternal postnatal 
depression. It is also likely that a number of women in the unexposed (control) group 
developed postnatal depression, which may be associated with child behavioural outcomes. 
This represents an important area for future research. 
A further limitation was that not all women completed the follow-up questionnaire, 
however, later sensitivity analyses using inverse probability weighting to account for loss to 
follow-up did little to change the risk estimates. While the potential for residual confounding 
remains, this suggests that loss to follow-up is unlikely to have substantially biased our 
findings. This low risk of bias is supported by a previous study estimating bias from loss to 
follow-up in the DNBC.27 This study also demonstrated that the presence of childhood 
developmental disorders at 7-years of age was associated with a non-statistically significant 
reduced likelihood of children being lost to follow-up (OR 0.87; 95% CI 0.63-1.20), 
suggesting this is unlikely to be another major source of bias.27 Additional limitations include 
relying on maternal self-reported depression and antidepressant use during pregnancy. 
Finally, the sample size does not permit any strong conclusion concerning specific type of 
antidepressant use during pregnancy, or in relation to dose and/or duration of antidepressant 
exposure.  
Interpretation 
Oberlander et al.,28 showed that infants exposed to SSRIs in utero have an attenuated 
response to acute pain during heel prick compared to infants who were not exposed to SSRIs. 
Follow-up evaluation of those same infants at 4 years of age (n=22), however, revealed no 
associations with internalising,21 externalising, and attentional behaviours20. In contrast to 
these outcomes, a small number of studies have demonstrated an association between 
prenatal antidepressant exposure and delayed psychomotor development.6, 22, 24 In the 
majority of cases, however, observed outcomes have largely remained within previously 
defined normal ranges of development. Therefore, the clinical relevance of such findings 
remains unknown. Furthermore, there remains significant potential for residual confounding 
due to underlying maternal disease, its severity and associated behaviours that contribute 
towards impaired neurodevelopmental outcomes in childhood. Separating the effects of 
antidepressant use from underlying maternal illness remains the major challenge, and so far 
only few studies have utilised stronger sibling designs or designs where both parent’s 
medication use and mental health status are taken into consideration in an attempt to delineate 
genetic and environmental contributors, in addition to confounding by indication.29 
While our findings are reassuring,  the potential for prenatal antidepressant exposure 
to be associated with neurodevelopmental abnormalities in later life cannot be ruled out.30  
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Although it was not possible to examine sex-specific differences in this study due to limited 
statistical power, future studies should consider the potential for such differences. Differences 
in outcomes according to child sex could relate to underlying differences in human brain 
development and function,31, 32 altered susceptibility to maternal depression and/or the use of 
antidepressants during pregnancy. There is evidence that long-term metabolic outcomes 
associated with exposure to maternal depression and/or antidepressant use may differ 
according to fetal sex,33-35 while potential differences in developmental outcomes are less 
clear6, 7. Additional areas of focus include the potential impact of differing levels of exposure 
(i.e. illness severity, antidepressant use) and/or timing of exposure to maternal depression and 
antidepressants during pregnancy. Such effects could be influenced by key genetic factors 
(e.g. pharmacogenomics). Lastly, future studies should address ways in which to maximise 
the effectiveness and benefits of antidepressant use during pregnancy. If underlying maternal 
depression during pregnancy is strongly associated with adverse behavioural outcomes in 
children at 7-years of age, efforts should focus on improving the management of depression 
in the antenatal and postnatal period to improve child development and wellbeing in later life. 
As such, further large population-based studies are required to investigate the potential 
adverse effects of in utero exposure to antidepressants on fetal brain development and child 
neurodevelopmental outcomes, with longer-term follow-up of children into adulthood 
required, in addition to consideration for differences in post-natal life of importance for child 
development. 
 
While the findings from this study support appropriate management of maternal 
depression during pregnancy with antidepressants, as with any clinical decision, there is a 
need to consider and balance the benefits and potential risks associated with medication use. 
This includes the recognition that antidepressant use occurs in the context of maternal 
psychiatric illness, with increasing evidence to suggest that the combination of both 
antidepressant use and maternal psychiatric illness is associated with a range of adverse 
pregnancy outcomes (e.g. preterm delivery).3  
 
Conclusion 
The results of this study suggest that independent of maternal illness, prenatal 
antidepressant exposure is not associated with an increased risk of behavioural problems in 
children at 7-years of age. While these findings may provide reassurance regarding the use of 
antidepressants in pregnancy, the outcomes evaluated in this study represent just one of many 
outcomes of interest to both clinicians and patients that contribute towards the benefit:risk 
assessment and should not be used in isolation to guide clinical decision making. 
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Table 1. Baseline Antenatal Maternal Characteristics According to Exposure to 
Antidepressants, Untreated Maternal Depression, or Neither, During Pregnancy  
Table 1. Baseline Antenatal Maternal Characteristics According to Exposure to 








 N % N % N % 
Age, years    
<20 0 0 3 1.3 180 0.4 
20-24 22 10.5 27  11.7 3709 7.6 
25-29 62 29.5 82 35.5 18 815 38.6 
30-34 87 41.4 76 32.9 18 546 38.1 
>35 39 18.6 43 18.6 7 487 15.4 
Missing 0  0  0  
Parity       
0 107 51.9 108 47.0 22 795 46.8 
>0 103 49.1 122 53.0 25 914  53.2 
Missing 0  1  28  
BMI, kg/m2       
<18.5 9 4.3 20 8.7 2 118 4.4 
18.6-24.9 145 69.1 147 63.6 33 225 68.2 
25-29.9 34 16.2 43 18.6 9 155 18.8 
≥30 22 10.5 21 9.1 4 239 8.7 
Missing 0  0  0  
Smoking       
No 114 54.3 141 61.0 37 589 77.1 
Yes       
1-10 cigarettes/day 73 34.8 65  28.1 8 681 17.8 
>10 cigarettes/day 23 10.9 25 10.8 2 467 5.1 
Missing 0  0  0  
Alcohol       
No 133 63.3 131 56.7 26 606 54.6 
Yes 77 36.7 100 43.3 22 085 45.4 
Missing 0  0  46  
Highest level of 
education 
      
High 146 70.2 130 56.5 33 763 69.5 
Middle 47  22.6 82  35.7 13 296 27.4 
 Low 15  7.2 18 7.8 1 537 3.2 
Missing 2  1  141  
Marital status       
Living with partner 197 93.8 217 93.9 47 907 98.3 
Living alone 13 6.2 14 6.1 808 1.7 
Missing 0  0  22  
 Mean SD Mean SD Mean SD 
Antenatal Mooda 5.3 3.7 8.1 4.3 2.7 2.4 
Missing 0  0  0  
Abbreviations: BMI, Body Mass Index; SD, Standard Deviation 
a Evaluated during second prenatal interview at 32 weeks gestation using a modified 
version of the Symptoms Check List (SCL-8d)1 
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Table 2. Behavioural Problem Scores in Children at 7-years of Age Following Exposure to Antidepressants, Untreated Maternal Depression, Or 














P for Antidepressants 
vs Unexposed 
 N % N % P-Valuea N % P-Valuea 
Total Difficulties Scoreb      
Normal (0-13) 193 91.9 201 87.0 0.191 45 679 93.8 0.358 
Borderline (14-16) 10 4.8 14 6.1  1 573 3.2  
Abnormal (17-40) 7 3.3 16 3.9  1 457 3.0  
Missing 0  0   28   
Internalising Problems      
Emotional Symptoms Score      
Normal (0-3) 164 78.1 171 74.0 0.373 42 003 86.2 0.003 
Borderline (4) 19 9.1 19 8.2  3 167 6.5  
Abnormal (5-10) 27 12.9 41 17.8  3 547 7.3  
Missing 0  0   21   
Peer Problems Score         
Normal (0-2) 169 88.6 196 84.9 0.468 44 581 91.5 0.167 
Borderline (3) 14 6.7 18 7.8  2 036 4.2  
Abnormal (4-10) 10 4.8 17 7.4  2 101 4.3  
Missing 0  0   19   
Externalising Problems      
Conduct Problems Score      
Normal (0-2) 165 78.6 175 75.8 0.730 41 918 86.0 0.008 
Borderline (3) 26 12.4 30 13.0  4 202 8.6  
Abnormal (4-10) 19 9.1 26 11.3  2 600 5.3  
Missing 0  0   17   
Hyperactivity-Inattention Score         
Normal (0-5) 190 90.5 198 85.7 0.212 44 525 91.4 0.754 
Borderline (6) 9 4.3 11 4.8  1 716 3.5  
Abnormal (7-10) 11 5.2 22 9.5  2 473 5.1  
Missing 0  0   23   
Other Measures      
Pro-Social Score      
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Normal (6-10) 202 96.2 209 90.5 0.045 45 953 94.3 0.528 
Borderline (5) 6 2.9 13 5.6  1 759 3.6  
Abnormal (0-4) 2 1.0 9 3.9  1 018 2.1  
Missing 0  0   7   
Impact Score         
Normal (0) 176 83.8 185 81.9 0.321 44 400 91.6 <0.001 
Borderline (1) 18 8.6 15 6.6  1 846 3.8  
Abnormal (2) 16 7.6 26 11.5  2 242 4.6  
Missing 0  5   249   
a Fisher’s Exact Test 
bTotal difficulties score calculated from emotional symptoms, peer problems, conduct problems and hyperactivity-inattention scores.  
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Table 3. RRs for Behavioural Problems in Children at 7-years of Age Following Exposure to Antidepressants, Untreated Maternal Depression, or 
Neither, During Pregnancy 
 Antidepressants vs Unexposed Antidepressants vs Untreated 
Depression 
Untreated Depression vs Unexposed 
 Adjusteda Adjusteda + 
Antenatal Mood 
Adjusteda Adjusteda + 
Antenatal Mood 
Adjusteda Adjusteda + 
Antenatal Mood 
 RR 95% CI RR 95% CI RR 95% CI RR 95% CI RR 95% CI RR 95% CI 
Total Difficulties Scoreb             
Abnormal 1.00 0.49, 2.05 0.68 0.34, 1.36 0.54 0.23, 1.30 0.84 0.31, 2.31 1.91 1.20, 3.04 0.89 0.55, 1.46 
Internalising Problems             
Emotional Symptoms Score             
Abnormal 1.68 1.18, 2.38 1.20 0.85, 1.70 0.74 0.47, 1.14 0.80 0.50, 1.28 2.24 1.69, 2.97 1.23 0.91, 1.66 
Peer Problems Score             
Abnormal 1.04 0.57, 1.91 0.82 0.45, 1.51 0.65 0.30, 1.42 0.76 0.32, 1.85 1.53 0.97, 2.43 0.96 0.59, 1.54 
Externalising Problems             
Conduct Problems Score             
Abnormal 1.58 1.03, 2.42 1.19 0.77, 1.83 0.82 0.47, 1.43 0.90 0.49, 1.67 1.83 1.27, 2.62 1.00 0.69, 1.46 
Hyperactivity-Inattention 
Score 
            
Abnormal 0.99 0.56, 1.75 0.78 0.44, 1.37 0.57 0.28, 1.19 0.75 0.34, 1.64 1.66 1.12, 2.46 1.02 0.68, 1.53 
Other Measures             
Pro-Social Score             
Abnormal 0.46 0.12, 1.82 0.40 0.10, 1.60 0.23 0.05, 1.18 0.19 0.05, 0.77 1.90 1.01, 3.62 1.39 0.71, 2.70 
Impact Score             
Abnormal 1.56 0.97, 2.52 1.15 0.71, 1.85 0.66 0.36, 1.20 0.76 0.40, 1.46 2.28 1.60, 3.25 1.22 0.84, 1.79 
Abbreviations: RR, Relative Risk; CI, Confidence Interval 
a Adjusted for child sex, maternal age, parity, smoking status, alcohol use, and socioeconomic status 
bTotal difficulties score calculated from emotional symptoms, peer problems, conduct problems and hyperactivity-inattention scores 
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Table S1. Characteristics of Eligible Women Lost and Not Lost to Follow-Up 
Characteristic Not Lost 
(N= 49 178) 
Lost 
(N= 30 929) 
 N % N % 
Age, years     
<20 183 0.4 258 0.8 
20-24 3 758 7.6 3 236 10.5 
25-29 18 959 38.6 12 054 39.0 
30-34 18 709 38.0 11 152 36.1 
>35 7 569 15.4 4 229 13.7 
Missing 0  0  
Parity     
0 23 010 46.8 14 299 46.3 
>0 26 139 53.2 16 610 53.7 
Missing 29  20  
BMI, mean, kg/m2     
<18.5 2 147 4.4 1 491 4.8 
18.6-24.9 33 517 68.2 19 557 63.2 
25-29.9 9 232 18.8 6 369 20.6 
≥30 4 282 8.7 3 512 11.4 
Missing 0  0  
Smoking     
No 37 844 76.9 21 955 71.0 
Yes     
1-10 cigarettes per d 8 819 17.9 6 645 21.5 
>10 cigarettes per d 2 515 5.1 2 329 7.5 
Missing 0  0  
Alcohol     
No 26 870 54.7 17 389 56.3 
Yes 22 262 45.3 13 504 43.7 
Missing 46  36  
Highest level of 
education 
    
High 34 039 69.4 19 495 63.3 
Middle 13 425 27.4 9 791 31.8 
Low 1 570 3.2 1 498 4.9 
Missing 144  145  
Marital status     
Living with partner 48 321 98.3 30 246 97.8 
Living alone 835 1.7 676 2.2 
Missing 22  7  
Exposure group    
Unexposed 48 737 99.1 30 501 98.6 
Untreated depression 231 0.5 243 0.8 
Antidepressant Use 210 0.4 185 0.6 
Missing 0  0  
a percentage calculated from non-missing values 
Table S2. Maternal Self-reported Antenatal Mood Symptoms According to Exposure 
to Antidepressants, Untreated Maternal Depression, or Neither, During Pregnancy 
Questiona Antidepressants Untreated Unexposed 
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interview (32 wk 




 N % N % N % 
Overall mood    
How have you felt 
on average during 
pregnancy? 
      
Very good 62 29.5 40 17.3 21 993 45.1 
Good 72 34.3 69 29.9 19 005 39.0 
Average 60 28.6 84 36.4 6 610 13.6 
Bad 12 5.7 25 10.8 958 2.0 
Very bad 4 1.9 13 5.6 153 0.3 
Missing 0  0  18  
Depression    
Have you felt that 
the future looked 
hopeless? 
   
No 135 64.3 106 45.9 43 881 90.1 
A little 53 25.2 66 28.6 4 316 8.9 
A lot 22 10.5 59 25.5 534 1.1 
Missing 0  0  6  
Have you felt sad or 
blue? 
      
No 77 36.7 20 8.7 30 717 63.0 
A little 91 43.3 108 46.8 16 597 34.1 
A lot 42 20.0 103 44.6 1 413 2.9 
Missing 0  0  10  
Have you felt that 
everything was a big 
effort? 
      
No 126 60.0 109 47.2 39 114 80.3 
A little 70 33.3 75 32.5 8 658 17.8 
A lot 14 6.7 47 20.4 955 2.0 
Missing 0  0  10  
Anxiety    
Have you felt scared 
or anxious without 
reason? 
   
No 103 49.3 88 38.1 35 445 72.8 
A little 84 40.2 85 36.8 11 699 24.0 
A lot 22 10.5 58 25.1 1 536 3.2 
Missing 1  0  57  
Have you felt 
nervous or at 
unease? 
      
No 78 37.1 46 20.0 32 953 67.6 
A little 104 49.5 120 52.2 14 647 30.1 
A lot 28 13.3 64 27.8 1 125 2.3 
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Missing 0  1  12  
Have you felt tense 
and exhausted? 
      
No 102 48.6 68 29.4 33 579 69.8 
A little 93 44.3 123 53.3 14 249 29.3 
A lot 15 7.1 40 17.3 890 1.8 
Missing 0  0  19  
Stress    
Have you felt under 
constant pressure? 
      
No 149 70.9 120 51.9 43 885 90.1 
A little 51 24.3 70 30.3 4 220 8.7 
A lot 10 4.8 41 17.8 625 1.3 
Missing 0  0  7  
Have you been more 
touchy and quick-
tempered than usual? 
      
No 69 32.9 55 23.9 20 265 41.6 
A little 100 47.6 93 40.4 24 700 50.7 
A lot 41 19.5 82 35.6 3 735 7.7 
Missing 0  1  61  
Have you felt that 
demands on you 
were too big? 
      
No 145 69.1 123 53.5 41 084 84.3 
A little 52 24.8 72 31.3 6 913 14.2 
A lot 13 6.2 35 15.2 727 1.5 
Missing 0  1  13  
a Questions taken from a modified version of the Symptoms Check List (SCL-8d)1 
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Table S3. RRs for Behavioural Outcomes in Children at 7-years of Age According to Exposure During Pregnancy Using Inverse 
Probability Weighting to Adjust for Loss to Follow-Up 
 Antidepressants vs Unexposed Antidepressants vs Untreated 
Depression 
Untreated Depression vs. 
Unexposed 
 Adjusteda Adjusteda + 
IPW 
Adjusteda Adjusteda + 
IPW 
Adjusteda Adjusteda + 
IPW 
 RR 95% CI RR 95% CI RR 95% CI RR 95% CI RR 95% CI RR 95% CI 
Total Difficulties Scoreb             
Abnormal 0.68 0.34, 1.36 0.74 0.37, 1.49 0.84 0.31, 2.31 0.93 0.34, 2.54 0.89 0.55, 1.46 0.88 0.54, 1.45 
Internalising Problems             
Emotional Symptoms Score             
Abnormal 1.20 0.85, 1.70 1.20 0.85, 1.69 0.80 0.50, 1.28 0.86 0.54, 1.37 1.23 0.91, 1.66 1.17 0.86, 1.59 
Peer Problems Score             
Abnormal 0.82 0.45, 1.51 0.81 0.44, 1.49 0.76 0.32, 1.85 0.81 0.33, 2.00 0.96 0.59, 1.54 0.89 0.54, 1.45 
Externalising Problems             
Conduct Problems Score             
Abnormal 1.19 0.77, 1.83 1.18 0.77, 1.82 0.90 0.49, 1.67 0.94 0.51, 1.74 1.00 0.69, 1.46 0.96 0.66, 1.40 
Hyperactivity-Inattention Score             
Abnormal 0.78 0.44, 1.37 0.84 0.48, 1.47 0.75 0.34, 1.64 0.79 0.36, 1.74 1.02 0.68, 1.53 1.05 0.70, 1.57 
Other Measures             
Pro-Social Score             
Abnormal 0.40 0.10, 1.60 0.36 0.09, 1.43 0.19 0.05, 0.77 0.17 0.04, 0.70 1.39 0.71, 2.70 1.30 0.66, 2.57 
Impact Score             
Abnormal 1.15 0.71, 1.85 1.10 0.68, 1.78 0.76 0.40, 1.46 0.72 0.38, 1.38 1.22 0.84, 1.79 1.22 0.83, 1.79 
Abbreviations: RR, Relative Risk; CI, Confidence Interval; IPW, Inverse Probability Weighting 
a Adjusted for child sex, maternal age, parity, smoking status, alcohol use, socioeconomic status, and antenatal mood 
bTotal difficulties score calculated from emotional symptoms, peer problems, conduct problems and hyperactivity-inattention scores.  
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Table S4. RRs for Behavioural Problems in Children at 7-years of Age According to Timing of 
Antidepressant Exposure During Pregnancy 
 Adjusteda Adjusteda + 
Antenatal Mood 
 RR 95% CI RR 95% CI 
Total Difficulties Scoreb     
Untreated depression (n=231) Ref  Ref  
Exposure at any point during pregnancy (n=210) 0.54 0.23, 1.30 0.84 0.31, 2.31 
First-trimester exposure only (n=49) 0.88 0.28-2.74 1.11 0.33-3.73 
Second/third-trimester exposure (n=161) 0.41 0.14-1.19 0.60 0.20-1.88 
Internalising Problems     
Emotional Symptoms Score     
Untreated depression (n=231) Ref  Ref  
Exposure at any point during pregnancy (n=210) 0.74 0.47, 1.14 0.80 0.50, 1.28 
First-trimester exposure only (n=49) 0.96 0.50-1.86 1.03 0.52-2.03 
Second/third-trimester exposure (n=161) 0.66 0.40-1.08 0.69 0.41-1.15 
Peer Problems Score     
Untreated depression (n=231) Ref  Ref  
Exposure at any point during pregnancy (n=210) 0.65 0.30, 1.42 0.76 0.32, 1.85 
First-trimester exposure only (n=49) 0.73 0.20-2.65 0.80 0.20-3.29 
Second/third-trimester exposure (n=161) 0.58 0.24-1.36 0.64 0.25-1.61 
Externalising Problems     
Conduct Problems Score     
Untreated depression (n=231) Ref  Ref  
Exposure at any point during pregnancy (n=210) 0.82 0.47, 1.43 0.90 0.49, 1.67 
First-trimester exposure only (n=49) 1.44 0.68-3.08 1.52 0.67-3.41 
Second/third-trimester exposure (n=161) 0.63 0.32-1.22 0.71 0.34-1.48 
Hyperactivity-Inattention Score     
Untreated depression (n=231) Ref  Ref  
Exposure at any point during pregnancy (n=210) 0.57 0.28, 1.19 0.75 0.34, 1.64 
First-trimester exposure only (n=49) 0.35 0.09-1.42 0.42 0.10-1.69 
Second/third-trimester exposure (n=161) 0.64 0.30-1.40 0.82 0.37-1.82 
Abbreviations: RR, Relative Risk; CI, Confidence Interval 
a Adjusted for child sex, maternal age, parity, smoking status, alcohol use, and socioeconomic status 
bTotal difficulties score calculated from emotional symptoms, peer problems, conduct problems and 
hyperactivity-inattention scores 
 
